Axitinib in the treatment of metastatic renal cell carcinoma

Thai H Ho, Eric Jonasch

Research output: Contribution to journalArticle

24 Citations (Scopus)

Abstract

Axitinib, an oral small-molecule tyrosine kinase inhibitor targeted to angiogenesis, has demonstrated activity in advanced renal cell carcinoma. Common side effects include hypertension, fatigue and dysphonia. Axitinib is currently awaiting approval as a second-line agent in the treatment of advanced renal cell carcinoma. Trials, which include treatment-naive patients, are ongoing and will study the benefit of axitinib in the first-line setting.

Original languageEnglish (US)
Pages (from-to)1247-1253
Number of pages7
JournalFuture Oncology
Volume7
Issue number11
DOIs
StatePublished - Nov 2011
Externally publishedYes

Fingerprint

Renal Cell Carcinoma
Dysphonia
Protein-Tyrosine Kinases
Fatigue
Therapeutics
Hypertension
axitinib

Keywords

  • AG 013736
  • angiogenesis
  • AXIS
  • axitinib
  • renal cell carcinoma
  • targeted therapy
  • VEGF

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Axitinib in the treatment of metastatic renal cell carcinoma. / Ho, Thai H; Jonasch, Eric.

In: Future Oncology, Vol. 7, No. 11, 11.2011, p. 1247-1253.

Research output: Contribution to journalArticle

Ho, Thai H ; Jonasch, Eric. / Axitinib in the treatment of metastatic renal cell carcinoma. In: Future Oncology. 2011 ; Vol. 7, No. 11. pp. 1247-1253.
@article{40b72184b2ef4e09a7418672961893ed,
title = "Axitinib in the treatment of metastatic renal cell carcinoma",
abstract = "Axitinib, an oral small-molecule tyrosine kinase inhibitor targeted to angiogenesis, has demonstrated activity in advanced renal cell carcinoma. Common side effects include hypertension, fatigue and dysphonia. Axitinib is currently awaiting approval as a second-line agent in the treatment of advanced renal cell carcinoma. Trials, which include treatment-naive patients, are ongoing and will study the benefit of axitinib in the first-line setting.",
keywords = "AG 013736, angiogenesis, AXIS, axitinib, renal cell carcinoma, targeted therapy, VEGF",
author = "Ho, {Thai H} and Eric Jonasch",
year = "2011",
month = "11",
doi = "10.2217/fon.11.107",
language = "English (US)",
volume = "7",
pages = "1247--1253",
journal = "Future Oncology",
issn = "1479-6694",
publisher = "Future Medicine Ltd.",
number = "11",

}

TY - JOUR

T1 - Axitinib in the treatment of metastatic renal cell carcinoma

AU - Ho, Thai H

AU - Jonasch, Eric

PY - 2011/11

Y1 - 2011/11

N2 - Axitinib, an oral small-molecule tyrosine kinase inhibitor targeted to angiogenesis, has demonstrated activity in advanced renal cell carcinoma. Common side effects include hypertension, fatigue and dysphonia. Axitinib is currently awaiting approval as a second-line agent in the treatment of advanced renal cell carcinoma. Trials, which include treatment-naive patients, are ongoing and will study the benefit of axitinib in the first-line setting.

AB - Axitinib, an oral small-molecule tyrosine kinase inhibitor targeted to angiogenesis, has demonstrated activity in advanced renal cell carcinoma. Common side effects include hypertension, fatigue and dysphonia. Axitinib is currently awaiting approval as a second-line agent in the treatment of advanced renal cell carcinoma. Trials, which include treatment-naive patients, are ongoing and will study the benefit of axitinib in the first-line setting.

KW - AG 013736

KW - angiogenesis

KW - AXIS

KW - axitinib

KW - renal cell carcinoma

KW - targeted therapy

KW - VEGF

UR - http://www.scopus.com/inward/record.url?scp=80455158267&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=80455158267&partnerID=8YFLogxK

U2 - 10.2217/fon.11.107

DO - 10.2217/fon.11.107

M3 - Article

C2 - 22044199

AN - SCOPUS:80455158267

VL - 7

SP - 1247

EP - 1253

JO - Future Oncology

JF - Future Oncology

SN - 1479-6694

IS - 11

ER -